Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Rhea-AI Summary

Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced it will host a webcast to discuss its Q4 and full-year 2024 financial results. The presentation will take place on Tuesday, February 11, 2025, at 8:00 a.m. ET. Management will provide both financial results and a corporate update during the event. Investors can access the webcast through the company's website under the 'Events and Presentations' section, and a replay will be available afterward.

News Market Reaction

-2.90%

1 alert

-2.90% News Effect

On the day this news was published, ARVN declined 2.90%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET.

The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

When will Arvinas (ARVN) report its Q4 2024 earnings?

Arvinas will report its Q4 and full year 2024 financial results on Tuesday, February 11, 2025, at 8:00 a.m. ET.

How can investors access Arvinas (ARVN) Q4 2024 earnings webcast?

Investors can access the webcast through the 'Events and Presentations' section on the investor page of the Arvinas website at www.arvinas.com.

Will there be a replay available for Arvinas (ARVN) Q4 2024 earnings call?

Yes, a replay of the webcast will be available on the Arvinas website following the completion of the event.

What will be covered in Arvinas (ARVN) February 11, 2025 webcast?

The webcast will cover Arvinas's Q4 and full year 2024 financial results and include a corporate update from management.